Specific Induction of Right Ventricular-like Cardiomyocytes from hPSCs: Technical Insights and Research Implications

Study Background and Research Question

Chamber-specific cardiomyocytes derived from human pluripotent stem cells (hPSCs) are increasingly valuable for modeling heart disease, drug screening, and regenerative medicine. However, most differentiation protocols yield populations resembling left ventricular (LV) cardiomyocytes, leaving a critical gap for researchers interested in right ventricular (RV) pathologies, including arrhythmogenic right ventricular cardiomyopathy and pulmonary hypertension-associated RV failure. Saito et al. sought to address whether hPSC-derived cardiomyocytes could be directed specifically toward an RV-like phenotype and to elucidate phenotypic differences between LV-like and RV-like hPSC-cardiomyocytes (Saito et al., 2025).

Key Innovation from the Reference Study

The major innovation of this work is the modification of established cardiac differentiation protocols to selectively induce RV-like cardiomyocytes from hPSCs. By fine-tuning the stage-specific modulation of signaling pathways, particularly Bone Morphogenetic Protein (BMP) and insulin signaling during mesoderm induction, the authors generated cardiac progenitor populations enriched for the anterior second heart field (SHF)—the embryological source of RV myocardium. This strategy enabled efficient production of cardiomyocytes with gene expression and functional properties characteristic of the RV (Saito et al., 2025).

Methods and Experimental Design Insights

The experimental approach builds upon the widely used GiWi protocol, which involves sequential GSK3β inhibition (Wnt activation) followed by Wnt inhibition to drive hPSC differentiation toward the cardiac lineage. Saito et al. introduced key modifications:

• During mesoderm formation, addition of insulin or BMP antagonists inhibited endogenous BMP signaling.
• Cardiac progenitor populations were assessed using established markers—TBX5 and NKX2-5—to distinguish first heart field (FHF, LV progenitors) from anterior SHF (RV progenitors).
• Downstream hPSC-cardiomyocytes were characterized for chamber-specific gene expression, spontaneous contraction rate, calcium handling, and cell size.

This systematic combination of developmental biology principles and marker-based validation allowed the team to map the impact of protocol alterations on cell fate outcomes (Saito et al., 2025).

Protocol Parameters

• assay: BMP pathway inhibition during mesoderm induction | value: Insulin or BMP antagonist (concentration and timing per GiWi modification) | applicability: RV-like cardiomyocyte generation | rationale: Shifts progenitor fate from FHF (LV-like) to anterior SHF (RV-like) | source: paper
• assay: GiWi protocol baseline | value: Sequential GSK3β inhibition, then Wnt inhibition | applicability: Baseline cardiac differentiation | rationale: Standard approach for generating hPSC-cardiomyocytes | source: paper
• assay: Cardiac progenitor marker assessment | value: TBX5+/NKX2-5+ (FHF) vs. TBX5−/NKX2-5+ (SHF) | applicability: Lineage tracing and validation | rationale: Distinguishes LV and RV progenitor populations | source: paper
• assay: Calcium transient measurement | value: Functional readout (no fixed numeric value) | applicability: Assessing contractile and electrophysiological phenotype | rationale: RV-like cells show distinct Ca2+ handling | source: paper

Core Findings and Why They Matter

The central findings of Saito et al. are as follows:

1. The standard GiWi protocol yields predominantly FHF-like progenitors, resulting in hPSC-cardiomyocytes with LV-like characteristics.
2. Inhibiting BMP signaling during mesoderm induction, via insulin or BMP antagonists, effectively suppresses FHF marker expression and enhances SHF marker expression—redirecting fate toward RV-like progenitors.
3. Resultant RV-like hPSC-cardiomyocytes display distinct transcriptomic and phenotypic signatures: elevated spontaneous contraction rates, altered calcium transients, and reduced cell size compared to LV-like counterparts.

These results fill a crucial gap for disease modeling and pharmacological testing of RV-specific cardiac disorders, where accurate chamber identity is key to translational relevance (Saito et al., 2025).

Comparison with Existing Internal Articles

While the reference study focuses on the developmental biology and protocol refinement for chamber-specific cardiomyocyte induction, several internal articles address complementary technical needs in cardiac and neurophysiological research. For example, "Veratridine: Transforming Sodium Channel Dynamics Research" details protocols for using Veratridine—a steroidal alkaloid neurotoxin and potent voltage-gated sodium channel opener—in the context of sodium channel dynamics and excitotoxicity studies. This is relevant because functional validation of differentiated cardiomyocytes often requires pharmacological tools that modulate sodium channel activity, enabling assessment of excitability and action potential propagation.

Additionally, articles such as "Veratridine: Mechanistic Insights for Sodium Channel Dynamics" and "Veratridine: A Precision Tool for Neurotoxicity and Cancer" provide comparative insights into the application of sodium channel openers in diverse systems, further contextualizing the importance of precise functional assays for chamber-specific cardiomyocyte maturation.

Limitations and Transferability

Despite the methodological advance, several limitations remain. The protocol requires further optimization for scalability and reproducibility across diverse hPSC lines. The study's functional characterization, while comprehensive, does not yet address long-term electrophysiological stability or responsiveness to pathophysiological stimuli relevant to adult RV disease. Furthermore, transferability to disease-specific iPSC lines and integration with three-dimensional or tissue-engineered platforms is not yet demonstrated (Saito et al., 2025).

Research Support Resources

For researchers aiming to functionally characterize hPSC-derived chamber-specific cardiomyocytes, specialized reagents are essential. Veratridine (SKU B7219), a well-characterized voltage-gated sodium channel opener, is widely used to probe sodium channel dynamics, excitability, and action potential properties in excitable cell types, including cardiomyocytes and neurons (source: internal_article). APExBIO offers Veratridine with validated purity and workflow protocols, supporting robust sodium channel modulation for both assay development and mechanistic studies (source: product_spec).